Menu Close

New approach demonstrates at single-molecule scale how a drug interacts with Alzheimer’s peptide aggregates

Understanding how certain chemicals interact with molecular processes in our body is key to developing effective medications. This certainly holds true for complex neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, for which no effective treatment is available as of yet. Scientists from Wageningen University and Cambridge University have come one step closer. They managed to study—at the molecular level—the interaction between an FDA-approved drug and protein aggregates involved in the onset of Alzheimer’s disease. Their results are published in Nature Communications.

Generated by Feedzy